[go: up one dir, main page]

WO1997020579A3 - Nouveaux composes et leur utilisation - Google Patents

Nouveaux composes et leur utilisation Download PDF

Info

Publication number
WO1997020579A3
WO1997020579A3 PCT/EP1996/005477 EP9605477W WO9720579A3 WO 1997020579 A3 WO1997020579 A3 WO 1997020579A3 EP 9605477 W EP9605477 W EP 9605477W WO 9720579 A3 WO9720579 A3 WO 9720579A3
Authority
WO
WIPO (PCT)
Prior art keywords
novel compounds
neurotoxins
neurotoxin
conjugates
fragments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1996/005477
Other languages
English (en)
Other versions
WO1997020579A2 (fr
Inventor
Jack Price
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of WO1997020579A2 publication Critical patent/WO1997020579A2/fr
Publication of WO1997020579A3 publication Critical patent/WO1997020579A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

On décrit l'utilisation de neurotoxines ou de fragments de celles-ci, pour transporter des acides nucléiques dans le système nerveux, ainsi que l'utilisation de conjugués comprenant une neurotoxine ou un fragment de celle-ci et un acide nucléique.
PCT/EP1996/005477 1995-12-05 1996-12-02 Nouveaux composes et leur utilisation Ceased WO1997020579A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9524807.6 1995-12-05
GBGB9524807.6A GB9524807D0 (en) 1995-12-05 1995-12-05 Novel compounds

Publications (2)

Publication Number Publication Date
WO1997020579A2 WO1997020579A2 (fr) 1997-06-12
WO1997020579A3 true WO1997020579A3 (fr) 1997-09-25

Family

ID=10784907

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1996/005477 Ceased WO1997020579A2 (fr) 1995-12-05 1996-12-02 Nouveaux composes et leur utilisation

Country Status (2)

Country Link
GB (1) GB9524807D0 (fr)
WO (1) WO1997020579A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19856052A1 (de) * 1998-12-04 2000-06-08 Deutsches Krebsforsch Konjugat zur Anreicherung in neuronalen Zellen
US6306403B1 (en) 2000-06-14 2001-10-23 Allergan Sales, Inc. Method for treating parkinson's disease with a botulinum toxin
CA2482904A1 (fr) * 2002-04-18 2003-10-23 Lynkeus Biotech Gmbh Moyens et procedes pour la modulation specifique de genes cibles dans le snc et l'oeil, et procedes pour leur identification
US7148342B2 (en) 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
US8609112B2 (en) 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US8734810B2 (en) 2003-10-29 2014-05-27 Allergan, Inc. Botulinum toxin treatments of neurological and neuropsychiatric disorders
US8609113B2 (en) 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US8617572B2 (en) 2003-10-29 2013-12-31 Allergan, Inc. Botulinum toxin treatments of depression
GB0725321D0 (en) * 2007-12-31 2008-02-06 Syntaxin Ltd Delivery vehicles
AU2009322279A1 (en) 2008-12-04 2011-07-14 Opko Pharmaceuticals, Llc Compositions and methods for selective inhibition of pro-angiogenic VEGF isoforms

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991000100A2 (fr) * 1989-06-29 1991-01-10 Institute For Animal Health Limited Utilisations d'une toxine
WO1995032738A1 (fr) * 1994-05-31 1995-12-07 Allergan, Inc. Modification de toxines de clostridium utilisees comme proteines de transport
WO1996004001A1 (fr) * 1994-08-05 1996-02-15 Molecular/Structural Biotechnologies, Inc. Complexes biomoleculaires diriges

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991000100A2 (fr) * 1989-06-29 1991-01-10 Institute For Animal Health Limited Utilisations d'une toxine
WO1995032738A1 (fr) * 1994-05-31 1995-12-07 Allergan, Inc. Modification de toxines de clostridium utilisees comme proteines de transport
WO1996004001A1 (fr) * 1994-08-05 1996-02-15 Molecular/Structural Biotechnologies, Inc. Complexes biomoleculaires diriges

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GOTTSCHALK S. ET AL.: "EFFICIENT GENE DELIVERY AND EXPRESSION IN MAMMALIAN CELLS USING DNA COUPLED WITH PERFRINGOLYSIN O.", GENE THERAPY, vol. 2, no. 7, September 1995 (1995-09-01), pages 498 - 503, XP002036157 *
JESUS FOMINAYA ET AL.: "TARGET CELL-SPECIFIC DNA TRANSFER MEDIATED BY A CHIMERIC MULTIDOMAIN PROTEIN.", JOURNAL OF BIOLOGICAL CHEMISTRY (MICROFILMS), vol. 18, 3 May 1996 (1996-05-03), MD US, pages 10560 - 10568, XP002036158 *

Also Published As

Publication number Publication date
WO1997020579A2 (fr) 1997-06-12
GB9524807D0 (en) 1996-02-07

Similar Documents

Publication Publication Date Title
AU6802994A (en) Nucleic acid analogue assay procedures
AU5788994A (en) Nucleic acid pharmaceuticals
DE69534778D1 (en) Cathepsin-02-protease
AU6058094A (en) Internal controls for iosthermal nucleic acid amplification reactions
AU6188096A (en) 4-substituted-phenyl-boronic acids as enzyme stabilizers
EP0623171A4 (fr) Molecules d'arn enzymatiques.
EP1293565A3 (fr) Composante ARN de la télomérase de mammifères
AU6191494A (en) Deoxyribonucleic acids
WO1995006731A3 (fr) Acide nucleique enzymatique contenant un non-nucleotide
AU4567499A (en) Novel mtbx protein and nucleic acid molecules and uses therefor
AU8740398A (en) Amplification of nucleic acids
AU7225591A (en) Nucleic acid enzymes for cleaving dna
AU5001496A (en) Introduction of dna into bacillus strains by conjugation
WO1996001614A3 (fr) Composant d'arn de la telomerase
AUPN741696A0 (en) Delivery of nucleic acids ii
WO1997020579A3 (fr) Nouveaux composes et leur utilisation
AU2646497A (en) Amplification of nucleic acids
AU6645294A (en) L-amino acid oxidase
GB9626074D0 (en) Nucleic acids amplification assay
AU6913394A (en) Nucleic acid tagged immunoassay
AU7136196A (en) Pharmaceutical composition which is useful for the transfection of nucleic acids, and uses thereof
AU3470195A (en) Nucleic acid fragment and products derived therefrom
EP0614970A3 (fr) Inhibiteurs de l'hydroxyphénylpyruvate-dioxygénase et test d'identification de l'enzyme.
AU7208394A (en) Improved nucleic acid reactions
AU5905094A (en) Nucleic acid assay procedure

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 97520998

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase